Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.57 |
| ▸ | TYMS | P04818 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263613 | 0.92 | DUT (0.73) | DUTP2RY2P2RY4P2RY6TYMS | |
| Deoxyuridine Monophosphate SCHEMBL25024676 | 0.91 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL21941035 | 0.91 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL8200 | 0.91 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL888328 | 0.91 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL20266308 | 0.89 | DUT (0.71) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL5565558 | 0.88 | DUT (0.73) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL5051998 | 0.88 | DUT (0.76) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL21067966 | 0.87 | DUT (0.78) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL21626116 | 0.87 | DUT (0.78) | DUTP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235650-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7125975-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7122649-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050158727-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-6919439-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050043219-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-6831166-B2 | Nucleoside composition for use as tool in human therapeutics and diagnositcs | ISIS PHARMACEUTICALS, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20030175751-A1 | Derivatized oligonucleotides having improved uptake and other properties | MANOHARAN MUTHIAH (US) | 2003-09-18 | — | — | US | disclosed |
| EP-1331011-A2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0724447-B1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030064492-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20020177150-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICAL, INC. | 2002-11-28 | — | — | US | disclosed |
| US-6395492-B1 | MONITORING CELLULAR INTAKE OF ADJUSTED NUCLEOSIDES; OBTAIN ORGANISM, INCUBATE WITH ADJUSTED NUCLEOSIDES, MONITOR CELL FOR REPORTER SIGNAL, PRESENCE INDICATES INTAKE | ISIS PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
| US-6153737-A | OLIGONUCLEOTIDES HAVING IMPROVED TRANSFER ACROSS CELLULAR MEMBRANES; FOR ASSAYING DISEASE STATES IN ANIMALS; HAVING IMPROVED TRANSFER AND UPTAKE PROPERTIES FOR TREATMENT OF DISEASES THROUGH MODULATION OF ACTIVITY OF DNA AND RNA | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0724447-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-07 | — | — | EP | disclosed |
| EP-0724447-A4 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS INC (US) | 1996-01-22 | — | — | EP | disclosed |
| WO-1993007883-A1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |